Form 4: Viracta Therapeutics CFO Acquires 200,000 Stock Options

Daniel Chevallard, CFO and COO of Viracta Therapeutics, acquired 200,000 stock options on March 12, 2024, according to a Form 4 filing with the SEC.

Summary

• Daniel R. Chevallard, CFO and COO of Viracta Therapeutics, Inc. (VIRX), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 12, 2024.
• Chevallard acquired 200,000 stock options with an exercise price of $0.985.
• These options vest monthly, with 1/48th of the total shares vesting each month starting January 1, 2024, subject to continued service.
• The options expire on March 12, 2034.
• Following the transaction, Chevallard directly owns 200,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently indicate positive or negative sentiment, but rather reports a transaction.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.

Stakeholder Impact

• The acquisition of stock options by a company executive can be viewed positively by shareholders as it aligns management's interests with the company's performance.

Key Dates

Keywords

Form 4, Viracta Therapeutics, Stock Options, Daniel Chevallard, Insider Trading, VIRX, SEC Filing, CFO, COO